255
Participants
Start Date
November 30, 2006
Primary Completion Date
December 31, 2008
Study Completion Date
March 31, 2009
ziprasidone
Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
Pfizer Investigational Site, Berlin
Pfizer Investigational Site, Staten Island
Pfizer Investigational Site, Athens
Pfizer Investigational Site, Olean
Pfizer Investigational Site, Hamburg
Pfizer Investigational Site, Hialeah
Pfizer Investigational Site, Miami
Pfizer Investigational Site, Miami
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Olive Branch
Pfizer Investigational Site, Düsseldorf
Pfizer Investigational Site, İzmit
Pfizer Investigational Site, Zamora
Pfizer Investigational Site, Des Plaines
Pfizer Investigational Site, Oakbrook Terrace
Pfizer Investigational Site, Schaumburg
Pfizer Investigational Site, Chicago
Pfizer Investigational Site, St Louis
Pfizer Investigational Site, Topeka
Pfizer Investigational Site, DeSoto
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, München
Pfizer Investigational Site, Phoenix
Pfizer Investigational Site, Las Vegas
Pfizer Investigational Site, Torrance
Pfizer Investigational Site, National City
Pfizer Investigational Site, San Diego
Pfizer Investigational Site, Temecula
Pfizer Investigational Site, Costa Mesa
Pfizer Investigational Site, Garden Grove
Pfizer Investigational Site, Bothell
Pfizer Investigational Site, Kirkland
Pfizer Investigational Site, Orange
Pfizer Investigational Site, Nashua
Pfizer Investigational Site, Aparecida de Goiânia
Pfizer Investigational Site, Rio de Janeiro
Pfizer Investigational Site, São Paulo
Pfizer Investigational Site, Thessaloniki
Pfizer Investigational Site, Ankara
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY